Koers ProtoKinetix, Incorporated Other OTC
Aandelen
PKTX
US7437221002
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 6,58 mln. 6,11 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -1 mln. -929K | Nettowinst (verlies) 2023 | - 0 | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 25,55K 23,74K | Nettoliquiditeiten 2023 | 20,41K 18,96K | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-4,29
x | K/w-verhouding 2023 |
-1,9
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 60,09% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Clarence Smith
CEO | Chief Executive Officer | 60 | 01-06-14 |
Michael Guzzetta
DFI | Director of Finance/CFO | 66 | 14-11-17 |
Victoria Bantz
LAW | General Counsel | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Clarence Smith
CEO | Chief Executive Officer | 60 | 01-06-14 |
Edward McDonough
BRD | Director/Board Member | 71 | 01-07-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 48,09 mld. | |
+46,90% | 40,62 mld. | |
-3,46% | 40,43 mld. | |
-6,20% | 28,36 mld. | |
+9,17% | 24,89 mld. | |
-20,42% | 19,01 mld. | |
+28,07% | 12,09 mld. | |
+0,17% | 11,88 mld. | |
-1,24% | 11,8 mld. |